FRM-II

ITM

HFR Petten/PALLAS (NRG)

Curium

BR2 (SCK CEN)

IRE

SHINE

EZAG

Monrol

NOVARTIS
AAA

Point BioPharma

ISOTOPIA

*building European and
Canadian facilities

Alpha 9 🇨🇦

3 Lutetium Trials
- 2 GEP NETs
- 1 Glioblastoma

4 Lutetium Trials - Prostate Cancer
- 3 Prostate
- 1 'Select Solid Tumours'

1 Lutetium trial - Prostate

8 Pancreatic/GEP NETs

13 Prostate
5 under Endocyte (acquired by Novartis)

11 Other Trials:

4 Neuroblastoma/Glioblastoma
Nasopharyngeal Cancer
Lung Cancer
Breast Cancer
Merkel Cell Carcinoma
Neoplasms
Carcinoid Heart Disease
'Solid Tumour' (Novartis acquired Clovis)

"Clinical trials of its therapeutic candidates for solid and hematologic malignancies"
Trial not found in database

a

Adding 4 production sites in 2023
- 3 commercial supply
- 1 research/clinical

ImaginAB

1 Trial - Solid Tumours
Trial not found in database

Reactor

Producer/Manufacturer

Commercial seller

Clinical Trials

2 Trials
Lung Cancer (non-small cell)
Breast/Gastric
Trial not found in database; preclinical

RadioPharm

Telix Pharma

2 Trials - Prostate Cancer

Jubliant

Pilochem | Seibersdorf

FutureChem

Lantheus

1 Lutetium trial on NETs (mid-gut)
posted as Progenics - bought by Lantheus)

Lutetium Trials
-Prostate
-Renal

Announced new N.A. facility
dedicated to Lu-177 Production

Opened new Lu-177
production site in Belgium

Opened NOVA, world's largest
Lu-177 facility in Germany